论文部分内容阅读
目的探讨尿激酶静脉溶栓治疗急性心肌梗死的临床疗效及安全性。方法分析2006年2月—2011年2月收住我科的38例急性心肌梗死患者的临床资料。结果本组冠脉再通29例,再通率76.3%;6例(15.8%)发生轻微出血并发症。结论尿激酶静脉溶栓治疗可靠、安全、使用方便、并发症发生率低且轻微。
Objective To investigate the clinical efficacy and safety of intravenous thrombolysis with urokinase in the treatment of acute myocardial infarction. Methods The clinical data of 38 patients with acute myocardial infarction admitted to our department from February 2006 to February 2011 were analyzed. Results The group of coronary recanalization in 29 cases, the pass rate was 76.3%; 6 cases (15.8%) occurred minor bleeding complications. Conclusion The urokinase intravenous thrombolysis is reliable, safe and easy to use. The incidence of complications is low and mild.